Hot Features
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhib... Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.87 | -13.997005988 | 13.36 | 13.535 | 11.49 | 230764 | 12.58645743 | CS |
| 4 | -3.12 | -21.3552361396 | 14.61 | 14.945 | 11.49 | 170474 | 13.29361507 | CS |
| 12 | -2.55 | -18.1623931624 | 14.04 | 15.66 | 11.49 | 270702 | 13.06579215 | CS |
| 26 | 0.47 | 4.26497277677 | 11.02 | 16.33 | 8.6 | 262699 | 13.00721083 | CS |
| 52 | 7.07 | 159.954751131 | 4.42 | 16.33 | 3.57 | 235352 | 10.88987231 | CS |
| 156 | -3.01 | -20.7586206897 | 14.5 | 22 | 3.35 | 154283 | 11.63138919 | CS |
| 260 | -3.01 | -20.7586206897 | 14.5 | 22 | 3.35 | 154283 | 11.63138919 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.